Abstracts tagged "prognostic factors"

Abstract Number: 0260 • ACR Convergence 2022
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
You-Jung Ha¹, Seunghwan Shin², SE RIM CHOI³, Eun Ha Kang¹ and Yun Jong Lee¹, ¹Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ²Lunit Inc, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: The primary target for the treatment of rheumatoid arthritis (RA) is achieving remission or low disease activity with proper use of DMARD. Besides controlling…
Abstract Number: 1024 • ACR Convergence 2022
Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance
Philipp Sewerin¹, stephanie Knippschild², Sabrina Tulka², Xenofon Baraliakos³ and Ralph Brinks², ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Chair for Medical Biometry and Epidemiology, Witten, Germany, ³Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Recently, we have reported an increase in the incidence and prevalence of patients with PsA in Germany based on claim data from 65 million…
Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica¹, Arturo Blazquez-Navarro², Jan Sokolar³, Moritz Anft⁴, Uta Kiltz⁵, Stephanie Pfaender⁶, Elena Vidal Blanco⁷, Timm Westhoff⁸, Nina Babel⁸, Ulrik Stervbo⁹ and Xenofon Baraliakos¹⁰, ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr Universität Bochum, Herne, Germany, ⁴Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universit t Bochum, Medical Department I, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ⁷Ruhr-University Bochum, Department of Molecular and Medical Virology, Bochum, Germany, ⁸Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁹Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ¹⁰Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…
Abstract Number: 0299 • ACR Convergence 2022
Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
Yoshiya Tanaka¹, Tatsuya Atsumi², Daniel Aletaha³, Robert Landewé⁴, Beatrix Bartok⁵, Alena Pechonkina⁶, Ling Han⁶, Kahaku Emoto⁷, Shungo Kano⁷, Vijay Rajendran⁸ and Tsutomu Takeuchi⁹, ¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²Hokkaido University, Sapporo, Japan, ³Medical University Vienna, Wien, Austria, ⁴Amsterdam University Medical Center, Meerssen, Netherlands, ⁵Gilead Sciences, Inc., La Jolla, CA, ⁶Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, K.K., Tokyo, Japan, ⁸Galapagos NV, Gent, Belgium, ⁹Keio University and Saitama Medical University, Tokyo, Japan
Background/Purpose: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice…
Abstract Number: 1057 • ACR Convergence 2022
Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study
Ivette Casafont-Solé¹, Laura Calvo², Anne Riveros-Frutos³, Carlos De la Puente Bujidos⁴, Pau Alcubilla⁵, Lourdes Mateo¹ and Ivan Castellví⁶, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain, ³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴Ramon y Cajal University Hospital, Madrid, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Pulmonary arterial hypertension (PAH) leads to a progressive right heart failure and death.PAH is a leading cause of death in Systemic Sclerosis (SSc). To…
Abstract Number: 1859 • ACR Convergence 2022
Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
Jun Nakamura, Takao Nagashima and Kojiro Sato, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: Interstitial Lung Disease (ILD) accompanied with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is usually rapidly progressive and life-threatening with poor prognosis. Although…
Abstract Number: 0319 • ACR Convergence 2022
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy
Daming Shao¹, Alejandra Londoño Jimenez², Maria Auxiliadora Salgado Guerrero³, Anna Broder⁴ and Shudan Wang⁵, ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²McFarland Clinic, Ames, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Approximately 10 to 30% of patients with LN progress…
Abstract Number: 1130 • ACR Convergence 2022
Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics
Carlos Pérez-Sánchez¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Ismael Sánchez-Pareja², Jerusalem Calvo-Gutierrez², Rafaela Ortega-Castro¹, Montserrat Romero-Gomez², María Ángeles Aguirre-Zamorano³, María Carmen Ábalos-Aguilera⁴, Nuria Barbarroja¹, José Perez-Venegas⁵, Mª Dolores Ruiz-Montesinos⁵, Carmen Dominguez⁵, Carlos Rodriguez-Escalera⁶, Carmen Romero-Barco⁶, Antonio Fernandez-Nebro⁷, Natalia Mena Vazquez⁷, Jose Luis Marenco⁸, Julia Uceda Montañez⁸, Charo Santos⁹, Eduardo Collantes¹, Alejandro Escudero-Contreras² and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Virgen Macarena University Hospital, Sevilla, Spain, ⁶Virgen de la Victoria Hospital, Málaga, Spain, ⁷Regional University Hospital of Málaga, Málaga, Spain, ⁸Virgen de Valme University Hospital, Sevilla, Spain, ⁹Virgen de Valme University Hospital, Málaga, Spain
Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses…
Abstract Number: 1957 • ACR Convergence 2022
Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis
Nikolet den Hollander¹, Marloes Verstappen², Bastiaan van Dijk³, Annette van der Helm-van Mil⁴ and Hanna van Steenbergen³, ¹Leids Universitair Medisch Centrum, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Centre (LUMC), Leiden, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Undifferentiated arthritis (UA) is considered to be heterogenous and consists of subgroups, this notion is affirmed by differences in disease course, varying from spontaneous…
Abstract Number: 0328 • ACR Convergence 2022
Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis
Sarah Dyball¹, Mia Rodziewicz¹, Claudia Mendoza Pinto², Ian N. Bruce³ and Ben Parker⁴, ¹The University of Manchester, Manchester, United Kingdom, ²Systemic Autoimmune Diseases Research Unit, High-Specialty Medical Unit-CIBIOR, Mexican Social Security Institute, Puebla, Mexico, ³Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ⁴Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…
Abstract Number: 1137 • ACR Convergence 2022
MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy
Kristin Wipfler¹, Joshua Baker² and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: MHC class I polypeptide-related sequence A (MICA) is a protein involved in the activation of NK and T cells. Variants within the MICA gene…
Abstract Number: 2022 • ACR Convergence 2022
Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
Gregoire Martin de Fremont¹, Nathalie Costedoat-Chalumeau², Rakiba Belkhir³, Gaelle Guettrot-Imbert⁴, Nathalie Morel⁴, Gaetane Nocturne⁵, Anna Molto⁶, Tiphaine Goulenok⁷, Elisabeth Diot⁸, Estibaliz Lazaro⁹, Laurent Perard¹⁰, Nicole Ferreira¹¹, Maelle Le Besnerais¹², Nicolas Limal⁷, Nihal Martis¹³, Noémie Abisror¹⁴, Odile Debouverie¹⁵, Christophe Richez¹⁶, Vincent Sobanski¹⁷, Francois Maurier¹⁸, Gaetan Sauvetre¹², Herve Levesque¹², Marie Agnes Timsit¹⁹, Nathalie Tieule¹³, Pauline Orquevaux²⁰, GEFA Collaborative group²¹, Matthieu Mahevas²², Celine Lartigau Roussin²³, Elodie Chauvet²⁴, Emilie Berthoux²⁵, Francoise Sarrot Reynauld²⁶, Loic Raffray²⁷, Marion Couderc²⁸, Nicolas Martin Silva²⁹, Noemie Jourde Chiche³⁰, Nicolas Belhomme³¹, Thierry Thomas³², Vincent Poindron³³, Viviane Queyrel¹³, Juliette Delforge³⁴, Camille Le Ray³⁵, Emmanuelle Pannier³⁵, Xavier Mariette³⁶, Veronique Le Guern⁴ and Raphaèle Seror³⁷, ¹Rheumatology department, Kremlin Bicêtre hospital, APHP, Paris, France, ²Inserm DR Paris 5, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Hôpital Cochin, Paris, France, ⁵APHP, Le Kremlin Bicêtre, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁷APHP, Paris, France, ⁸CHU Tours, Tours, France, ⁹Bordeaux Hospital University, Bordeaux, France, ¹⁰CHU Lyon, Lyon, France, ¹¹department of Internal Medecine, CHU de Tours, Tours, France, ¹²CHU Rouen, Rouen, France, ¹³CHU Nice, Nice, France, ¹⁴Hopital Saint Antoine, Paris, France, ¹⁵CHU Poitiers, Poitiers, France, ¹⁶Université de Bordeaux, Bordeaux, France, ¹⁷Université de Lille, Lille, France, ¹⁸Hôpitaux privés de Metz, Metz, France, ¹⁹CHU Brest, Brest, France, ²⁰CHU Reims, Reims, France, ²¹Saint Joseph Hospital, Marseille, France, ²²CHU Mondor, Creteil, France, ²³CH La Réunion, CH la Réunion, France, ²⁴CH Cabestany, Cabestany, France, ²⁵CH Saint Joseph Saint Luc, Lyon, France, ²⁶CHU Grenoble, CHU Grenoble, France, ²⁷CH St Denis Reunion, Saint Denis Reunion, France, ²⁸University Hospital, Clermont-Ferrand, France, ²⁹CHU Caen, Caen, France, ³⁰APHM, Marseille, France, ³¹CHU Rennes, Rennes, France, ³²CHU Saint Etienne, Saint Etienne, France, ³³Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ³⁴Jean Verfier, Bobigny, France, ³⁵Port Royal, Paris, France, ³⁶Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ³⁷University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: In the context of primary Sjögren's syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes…
Abstract Number: 0329 • ACR Convergence 2022
Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression
Daniel Toro-Domínguez¹, Manuel Martinez-Bueno¹, Raúl López-Domínguez², Jordi Martorell-Marugán¹, Elena Carnero-Montoro¹, Guillermo Barturen¹, Daniel W. Goldman³, Michelle Petri³, Pedro Carmona-Sáez² and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Granada, Granada, Spain, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the…
Abstract Number: 1154 • ACR Convergence 2022
Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells
Aneta Pekčcová¹, Kristýna Bubová², Monika Gregova³, Šárka Forejtová², Jana Hořínková², Markéta Hušáková², Michal Tomcik⁴, Jindřiška Gatterová², Jiří Vencovský⁵, Karel Pavelka⁶, Ladislav Šenolt⁵ and Jiří Baloun², ¹Institue of Rheumatology, Prague, Prague, Czech Republic, ²Institue of Rheumatology, Prague, Czech Republic, ³Institue of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic
Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs, which are essential for correct gene expression. The dysregulation in miRNA expression is accompanied by various diseases and…
Abstract Number: 2049 • ACR Convergence 2022
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Phoung Phoung Diep¹, Karoline Lerang², Birgir Gudbransson¹, Helena Andersson¹, Øyvind Midtvedt¹, Torhild Garen¹, Michael Durheim¹, Trond Mogens Aaløkken¹, Øyvind Palm¹ and Øyvind Molberg², ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].